Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lung Transplantation | 64 | 2024 | 1305 | 9.960 |
Why?
|
HLA Antigens | 10 | 2024 | 1368 | 2.960 |
Why?
|
Isoantibodies | 6 | 2021 | 661 | 1.960 |
Why?
|
Lymphangioleiomyomatosis | 12 | 2023 | 203 | 1.840 |
Why?
|
Bronchiolitis Obliterans | 6 | 2024 | 213 | 1.730 |
Why?
|
Lung Diseases, Interstitial | 12 | 2023 | 911 | 1.640 |
Why?
|
Idiopathic Pulmonary Fibrosis | 12 | 2023 | 502 | 1.530 |
Why?
|
Tissue Donors | 11 | 2024 | 2313 | 1.520 |
Why?
|
Primary Graft Dysfunction | 5 | 2021 | 111 | 1.460 |
Why?
|
Connective Tissue Diseases | 3 | 2024 | 286 | 1.350 |
Why?
|
Histocompatibility Testing | 7 | 2024 | 717 | 1.240 |
Why?
|
Gastroesophageal Reflux | 12 | 2024 | 816 | 1.230 |
Why?
|
Lung Diseases | 8 | 2024 | 1915 | 1.200 |
Why?
|
Graft Rejection | 17 | 2024 | 4426 | 1.090 |
Why?
|
Pulmonary Fibrosis | 5 | 2023 | 506 | 0.880 |
Why?
|
Photopheresis | 2 | 2021 | 35 | 0.740 |
Why?
|
Histocompatibility | 2 | 2018 | 316 | 0.680 |
Why?
|
Vascular Endothelial Growth Factor D | 3 | 2017 | 64 | 0.650 |
Why?
|
Drug Labeling | 1 | 2021 | 251 | 0.640 |
Why?
|
Esophageal pH Monitoring | 11 | 2024 | 201 | 0.620 |
Why?
|
Carbon Monoxide | 3 | 2019 | 540 | 0.600 |
Why?
|
Sirolimus | 7 | 2019 | 1547 | 0.570 |
Why?
|
Heart Transplantation | 4 | 2023 | 3224 | 0.550 |
Why?
|
Survival Rate | 10 | 2024 | 12808 | 0.500 |
Why?
|
Preoperative Period | 3 | 2016 | 555 | 0.490 |
Why?
|
Sarcoma, Kaposi | 1 | 2018 | 376 | 0.490 |
Why?
|
Tissue and Organ Procurement | 2 | 2020 | 944 | 0.470 |
Why?
|
Hospitalization | 4 | 2019 | 10790 | 0.460 |
Why?
|
Postoperative Complications | 8 | 2024 | 15697 | 0.440 |
Why?
|
Immunomodulation | 1 | 2017 | 547 | 0.430 |
Why?
|
Esophagitis, Peptic | 2 | 2023 | 76 | 0.420 |
Why?
|
Respiratory Tract Infections | 3 | 2017 | 1007 | 0.400 |
Why?
|
Transplantation | 1 | 2013 | 218 | 0.380 |
Why?
|
Inhalation Exposure | 1 | 2013 | 429 | 0.370 |
Why?
|
Lung Neoplasms | 8 | 2023 | 13262 | 0.360 |
Why?
|
Retrospective Studies | 41 | 2024 | 80372 | 0.360 |
Why?
|
Burkholderia Infections | 2 | 2022 | 41 | 0.360 |
Why?
|
Venous Thromboembolism | 1 | 2023 | 1864 | 0.350 |
Why?
|
Delirium | 1 | 2022 | 1663 | 0.350 |
Why?
|
Graft Survival | 5 | 2024 | 3794 | 0.340 |
Why?
|
Middle Aged | 63 | 2024 | 220352 | 0.340 |
Why?
|
Antibodies | 1 | 2017 | 2421 | 0.340 |
Why?
|
Antibiotics, Antineoplastic | 3 | 2019 | 675 | 0.330 |
Why?
|
Immunosuppressive Agents | 7 | 2023 | 4166 | 0.330 |
Why?
|
Humans | 107 | 2024 | 760621 | 0.330 |
Why?
|
Lung | 14 | 2023 | 9994 | 0.310 |
Why?
|
Time Factors | 12 | 2023 | 40165 | 0.310 |
Why?
|
Vascular Endothelial Growth Factor Receptor-3 | 2 | 2018 | 119 | 0.280 |
Why?
|
Male | 64 | 2024 | 359744 | 0.270 |
Why?
|
Aged | 39 | 2024 | 169152 | 0.270 |
Why?
|
Female | 70 | 2024 | 391270 | 0.270 |
Why?
|
Organ Transplantation | 3 | 2022 | 1150 | 0.260 |
Why?
|
Length of Stay | 2 | 2020 | 6479 | 0.250 |
Why?
|
Burkholderia cepacia complex | 2 | 2022 | 24 | 0.250 |
Why?
|
Esophageal Motility Disorders | 2 | 2023 | 48 | 0.250 |
Why?
|
Patient Discharge | 1 | 2018 | 3476 | 0.250 |
Why?
|
Treatment Outcome | 19 | 2024 | 65017 | 0.250 |
Why?
|
Patient Readmission | 2 | 2016 | 3323 | 0.240 |
Why?
|
Cystic Fibrosis | 3 | 2018 | 1274 | 0.240 |
Why?
|
Immunologic Factors | 1 | 2014 | 1588 | 0.240 |
Why?
|
Rectal Diseases | 1 | 2005 | 144 | 0.230 |
Why?
|
Hospital Mortality | 1 | 2018 | 5425 | 0.230 |
Why?
|
Hyaluronic Acid | 2 | 2019 | 482 | 0.230 |
Why?
|
Colonic Diseases | 1 | 2005 | 200 | 0.230 |
Why?
|
Electric Impedance | 8 | 2023 | 755 | 0.230 |
Why?
|
Proportional Hazards Models | 6 | 2024 | 12531 | 0.230 |
Why?
|
Antiviral Agents | 3 | 2019 | 3061 | 0.220 |
Why?
|
Hydroxychloroquine | 2 | 2018 | 427 | 0.220 |
Why?
|
Adult | 43 | 2024 | 219994 | 0.220 |
Why?
|
Burkholderia cepacia | 1 | 2022 | 22 | 0.210 |
Why?
|
Follow-Up Studies | 12 | 2024 | 39261 | 0.210 |
Why?
|
Prognosis | 10 | 2024 | 29658 | 0.200 |
Why?
|
Vital Capacity | 5 | 2017 | 965 | 0.200 |
Why?
|
Pseudomonas | 1 | 2022 | 123 | 0.200 |
Why?
|
Interferon Type I | 1 | 2006 | 559 | 0.200 |
Why?
|
Telomere | 3 | 2021 | 933 | 0.200 |
Why?
|
Extracorporeal Membrane Oxygenation | 3 | 2022 | 1459 | 0.190 |
Why?
|
Enoxaparin | 1 | 2023 | 397 | 0.190 |
Why?
|
TOR Serine-Threonine Kinases | 3 | 2017 | 2058 | 0.190 |
Why?
|
Delivery of Health Care | 1 | 2019 | 5325 | 0.180 |
Why?
|
Anxiety | 1 | 2015 | 4538 | 0.180 |
Why?
|
Sarcoidosis | 1 | 2006 | 520 | 0.180 |
Why?
|
Hydrogen-Ion Concentration | 7 | 2023 | 2502 | 0.180 |
Why?
|
Resource Allocation | 1 | 2023 | 349 | 0.180 |
Why?
|
Air Pollution | 1 | 2013 | 2317 | 0.170 |
Why?
|
Arthritis, Psoriatic | 1 | 2022 | 219 | 0.170 |
Why?
|
Air Pollutants | 1 | 2013 | 2844 | 0.170 |
Why?
|
Health Care Rationing | 1 | 2023 | 435 | 0.170 |
Why?
|
Psychomotor Agitation | 1 | 2022 | 305 | 0.170 |
Why?
|
Fibrosis | 3 | 2023 | 2042 | 0.170 |
Why?
|
Incidence | 8 | 2023 | 21392 | 0.160 |
Why?
|
Polyamines | 1 | 2019 | 133 | 0.160 |
Why?
|
Endostatins | 1 | 2019 | 168 | 0.160 |
Why?
|
Acetyl-CoA Carboxylase | 1 | 2018 | 72 | 0.160 |
Why?
|
Hermanski-Pudlak Syndrome | 1 | 2018 | 20 | 0.150 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 2020 | 321 | 0.150 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2024 | 1355 | 0.150 |
Why?
|
Carbamates | 1 | 2019 | 192 | 0.150 |
Why?
|
Quality of Life | 2 | 2018 | 13308 | 0.150 |
Why?
|
Respiratory Function Tests | 4 | 2020 | 1683 | 0.140 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2021 | 1006 | 0.140 |
Why?
|
Steroids | 1 | 2022 | 928 | 0.140 |
Why?
|
Chronic Disease | 4 | 2024 | 9287 | 0.140 |
Why?
|
Forced Expiratory Volume | 6 | 2019 | 1809 | 0.140 |
Why?
|
Personal Autonomy | 1 | 2019 | 302 | 0.140 |
Why?
|
Vesicular Transport Proteins | 1 | 2019 | 374 | 0.140 |
Why?
|
Catheters, Indwelling | 1 | 2019 | 428 | 0.130 |
Why?
|
Adjustment Disorders | 1 | 2016 | 67 | 0.130 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2021 | 730 | 0.130 |
Why?
|
Depression | 1 | 2015 | 8044 | 0.130 |
Why?
|
Risk Factors | 11 | 2024 | 74359 | 0.130 |
Why?
|
Glomerular Mesangium | 2 | 2001 | 98 | 0.130 |
Why?
|
Embolism, Fat | 1 | 2015 | 46 | 0.130 |
Why?
|
Autoantibodies | 1 | 2024 | 2118 | 0.130 |
Why?
|
Arthritis, Rheumatoid | 2 | 2022 | 3763 | 0.130 |
Why?
|
Vascular Endothelial Growth Factor C | 1 | 2015 | 127 | 0.120 |
Why?
|
Patient Selection | 3 | 2021 | 4283 | 0.120 |
Why?
|
Proton Pump Inhibitors | 2 | 2017 | 551 | 0.120 |
Why?
|
Carcinoma, Bronchogenic | 1 | 2015 | 86 | 0.120 |
Why?
|
Fibrinogen | 1 | 2018 | 886 | 0.120 |
Why?
|
Decision Making | 2 | 2019 | 3925 | 0.120 |
Why?
|
Cryopreservation | 1 | 2020 | 717 | 0.120 |
Why?
|
Postoperative Period | 2 | 2016 | 1818 | 0.120 |
Why?
|
Lymphangiogenesis | 1 | 2015 | 172 | 0.120 |
Why?
|
Biological Specimen Banks | 1 | 2020 | 783 | 0.110 |
Why?
|
Pyridones | 1 | 2019 | 792 | 0.110 |
Why?
|
Hepatitis B Antibodies | 1 | 2014 | 157 | 0.110 |
Why?
|
Lymphoproliferative Disorders | 1 | 2017 | 533 | 0.110 |
Why?
|
Opportunistic Infections | 1 | 2017 | 377 | 0.110 |
Why?
|
Cohort Studies | 10 | 2019 | 41335 | 0.110 |
Why?
|
Catheterization, Central Venous | 1 | 2019 | 526 | 0.110 |
Why?
|
Hepatitis C | 2 | 2019 | 1579 | 0.110 |
Why?
|
Hepatitis B Vaccines | 1 | 2014 | 186 | 0.110 |
Why?
|
Kaplan-Meier Estimate | 4 | 2024 | 6544 | 0.110 |
Why?
|
Cross Infection | 1 | 2022 | 1434 | 0.110 |
Why?
|
Transplants | 1 | 2015 | 206 | 0.110 |
Why?
|
Telomerase | 2 | 2015 | 746 | 0.110 |
Why?
|
Maximum Tolerated Dose | 1 | 2015 | 877 | 0.100 |
Why?
|
Leukocytes, Mononuclear | 1 | 2019 | 1827 | 0.100 |
Why?
|
Bronchi | 1 | 2016 | 848 | 0.100 |
Why?
|
Risk Assessment | 4 | 2018 | 24123 | 0.100 |
Why?
|
Antineoplastic Agents | 1 | 2015 | 13630 | 0.100 |
Why?
|
Autoimmune Diseases | 1 | 2024 | 2250 | 0.100 |
Why?
|
Herpesvirus 4, Human | 1 | 2017 | 1075 | 0.100 |
Why?
|
Hepacivirus | 1 | 2019 | 1334 | 0.100 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2017 | 608 | 0.090 |
Why?
|
Indoles | 1 | 2019 | 1829 | 0.090 |
Why?
|
Absorptiometry, Photon | 1 | 2017 | 1736 | 0.090 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2021 | 2873 | 0.090 |
Why?
|
Mycobacterium | 1 | 2012 | 250 | 0.090 |
Why?
|
Lung Injury | 1 | 2015 | 424 | 0.090 |
Why?
|
Registries | 2 | 2024 | 8469 | 0.090 |
Why?
|
Cautery | 1 | 1990 | 71 | 0.090 |
Why?
|
Duodenal Diseases | 1 | 1990 | 99 | 0.090 |
Why?
|
Prospective Studies | 6 | 2023 | 54303 | 0.090 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2017 | 1215 | 0.090 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2019 | 10827 | 0.080 |
Why?
|
Enzyme Inhibitors | 2 | 2018 | 3726 | 0.080 |
Why?
|
Confidence Intervals | 1 | 2015 | 2932 | 0.080 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 2282 | 0.080 |
Why?
|
Kidney Transplantation | 1 | 2024 | 4215 | 0.080 |
Why?
|
Young Adult | 10 | 2019 | 58741 | 0.080 |
Why?
|
Mood Disorders | 1 | 2016 | 1124 | 0.080 |
Why?
|
Boston | 2 | 2019 | 9280 | 0.080 |
Why?
|
Family | 1 | 2020 | 3189 | 0.080 |
Why?
|
Cyclosporins | 1 | 1989 | 216 | 0.080 |
Why?
|
Mycoses | 1 | 2012 | 387 | 0.080 |
Why?
|
Hepatitis B | 1 | 2014 | 701 | 0.080 |
Why?
|
Survival Analysis | 2 | 2019 | 10182 | 0.080 |
Why?
|
Intensive Care Units | 1 | 2022 | 3736 | 0.080 |
Why?
|
Transplantation, Homologous | 2 | 2016 | 4810 | 0.080 |
Why?
|
Pilot Projects | 2 | 2019 | 8555 | 0.070 |
Why?
|
United States | 10 | 2024 | 72461 | 0.070 |
Why?
|
Anticoagulants | 1 | 2023 | 4897 | 0.070 |
Why?
|
Genetic Testing | 1 | 2021 | 3531 | 0.070 |
Why?
|
Waiting Lists | 2 | 2024 | 763 | 0.070 |
Why?
|
Antifungal Agents | 1 | 2012 | 749 | 0.070 |
Why?
|
Meclofenamic Acid | 1 | 1986 | 23 | 0.070 |
Why?
|
Drug Administration Schedule | 1 | 2015 | 4899 | 0.070 |
Why?
|
Antibodies, Viral | 1 | 2017 | 3143 | 0.070 |
Why?
|
Double-Blind Method | 5 | 2022 | 12427 | 0.070 |
Why?
|
Cytomegalovirus Infections | 1 | 2012 | 831 | 0.070 |
Why?
|
Gene Expression Regulation | 2 | 2021 | 11903 | 0.060 |
Why?
|
Tomography, X-Ray Computed | 3 | 2020 | 20509 | 0.060 |
Why?
|
Respiratory Insufficiency | 1 | 2014 | 1231 | 0.060 |
Why?
|
Administration, Inhalation | 2 | 2019 | 1156 | 0.060 |
Why?
|
Preoperative Care | 1 | 2014 | 2256 | 0.060 |
Why?
|
Combined Modality Therapy | 1 | 2017 | 8552 | 0.060 |
Why?
|
Mass Screening | 1 | 2021 | 5423 | 0.060 |
Why?
|
Bone Marrow | 1 | 2015 | 2912 | 0.060 |
Why?
|
Biopsy | 2 | 2015 | 6771 | 0.060 |
Why?
|
Anxiety Disorders | 1 | 2016 | 2714 | 0.060 |
Why?
|
Receptor, Angiotensin, Type 1 | 1 | 2024 | 148 | 0.060 |
Why?
|
Odds Ratio | 1 | 2016 | 9716 | 0.060 |
Why?
|
Liver | 2 | 2020 | 7509 | 0.060 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 2 | 2015 | 3224 | 0.050 |
Why?
|
Massachusetts | 1 | 2016 | 8803 | 0.050 |
Why?
|
Surgical Wound Infection | 1 | 2012 | 1527 | 0.050 |
Why?
|
Autophagy | 2 | 2022 | 1337 | 0.050 |
Why?
|
Colitis | 2 | 1989 | 1229 | 0.050 |
Why?
|
Drug Contamination | 1 | 2022 | 152 | 0.050 |
Why?
|
Manometry | 1 | 2023 | 453 | 0.050 |
Why?
|
Practice Guidelines as Topic | 1 | 2018 | 7475 | 0.050 |
Why?
|
Disease Progression | 3 | 2023 | 13502 | 0.050 |
Why?
|
Protein Kinase Inhibitors | 1 | 2017 | 5643 | 0.040 |
Why?
|
Endothelin-1 | 1 | 2001 | 302 | 0.040 |
Why?
|
Hepatitis C Antibodies | 1 | 2019 | 145 | 0.040 |
Why?
|
Electric Injuries | 1 | 1998 | 25 | 0.040 |
Why?
|
Aged, 80 and over | 7 | 2020 | 58995 | 0.040 |
Why?
|
ROC Curve | 2 | 2016 | 3568 | 0.040 |
Why?
|
Severity of Illness Index | 3 | 2017 | 15840 | 0.040 |
Why?
|
Constriction, Pathologic | 1 | 2021 | 1098 | 0.040 |
Why?
|
Endothelial Cells | 2 | 2024 | 3539 | 0.040 |
Why?
|
Carboxyhemoglobin | 1 | 2017 | 80 | 0.040 |
Why?
|
Adolescent | 5 | 2019 | 87810 | 0.040 |
Why?
|
North Carolina | 1 | 2018 | 325 | 0.040 |
Why?
|
Oxidative Phosphorylation | 1 | 2019 | 495 | 0.040 |
Why?
|
Specialization | 1 | 2022 | 778 | 0.040 |
Why?
|
Bronchoalveolar Lavage Fluid | 1 | 2019 | 748 | 0.040 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2001 | 1246 | 0.030 |
Why?
|
Failure to Thrive | 1 | 1997 | 140 | 0.030 |
Why?
|
Mutation | 3 | 2015 | 29932 | 0.030 |
Why?
|
Recombinant Proteins | 1 | 2006 | 6538 | 0.030 |
Why?
|
Hematologic Diseases | 1 | 2020 | 496 | 0.030 |
Why?
|
Water | 1 | 2022 | 1407 | 0.030 |
Why?
|
Prevalence | 3 | 2020 | 15687 | 0.030 |
Why?
|
Morbidity | 1 | 2021 | 1765 | 0.030 |
Why?
|
Calcium | 1 | 1989 | 5725 | 0.030 |
Why?
|
Mucositis | 1 | 2017 | 108 | 0.030 |
Why?
|
RNA, Viral | 3 | 2019 | 2838 | 0.030 |
Why?
|
Bronchodilator Agents | 1 | 2019 | 506 | 0.030 |
Why?
|
Safety | 1 | 2020 | 1148 | 0.030 |
Why?
|
Benchmarking | 1 | 2022 | 1044 | 0.030 |
Why?
|
Research Report | 1 | 2018 | 370 | 0.030 |
Why?
|
Premenopause | 1 | 2019 | 1038 | 0.030 |
Why?
|
HIV Seropositivity | 2 | 1997 | 955 | 0.030 |
Why?
|
Growth | 1 | 1996 | 365 | 0.030 |
Why?
|
Blood Cell Count | 1 | 2015 | 397 | 0.030 |
Why?
|
Acute Disease | 2 | 2015 | 7269 | 0.030 |
Why?
|
Referral and Consultation | 1 | 2007 | 3598 | 0.030 |
Why?
|
Comorbidity | 2 | 2020 | 10551 | 0.030 |
Why?
|
Down-Regulation | 1 | 2021 | 2913 | 0.030 |
Why?
|
Liver Function Tests | 1 | 2015 | 524 | 0.030 |
Why?
|
Immunization Schedule | 1 | 2014 | 224 | 0.030 |
Why?
|
Molecular Weight | 1 | 2015 | 2186 | 0.030 |
Why?
|
Genetic Markers | 1 | 2019 | 2608 | 0.030 |
Why?
|
Collagen | 1 | 2001 | 2636 | 0.030 |
Why?
|
Nervous System | 1 | 1996 | 543 | 0.030 |
Why?
|
Disease Outbreaks | 1 | 2022 | 1758 | 0.030 |
Why?
|
Pedigree | 1 | 2021 | 4578 | 0.030 |
Why?
|
Sensitivity and Specificity | 2 | 2019 | 14660 | 0.030 |
Why?
|
Gene Silencing | 1 | 2019 | 1513 | 0.030 |
Why?
|
Mycobacterium avium Complex | 1 | 2012 | 59 | 0.030 |
Why?
|
Echinocandins | 1 | 2012 | 51 | 0.030 |
Why?
|
Lipopeptides | 1 | 2012 | 72 | 0.030 |
Why?
|
Case-Control Studies | 2 | 2020 | 22053 | 0.030 |
Why?
|
Amphotericin B | 1 | 2012 | 142 | 0.030 |
Why?
|
Drug Monitoring | 1 | 2018 | 965 | 0.030 |
Why?
|
Longitudinal Studies | 2 | 2019 | 14495 | 0.020 |
Why?
|
Consensus | 1 | 2021 | 3113 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2019 | 6131 | 0.020 |
Why?
|
Pandemics | 2 | 2022 | 8624 | 0.020 |
Why?
|
Immunocompromised Host | 1 | 2017 | 857 | 0.020 |
Why?
|
Lymphatic Vessels | 1 | 2015 | 358 | 0.020 |
Why?
|
Area Under Curve | 1 | 2015 | 1636 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2019 | 3775 | 0.020 |
Why?
|
Tuberous Sclerosis | 1 | 2019 | 1030 | 0.020 |
Why?
|
Prednisone | 1 | 2015 | 1565 | 0.020 |
Why?
|
Duodenoscopy | 1 | 1990 | 45 | 0.020 |
Why?
|
Fatal Outcome | 1 | 2015 | 1832 | 0.020 |
Why?
|
Observer Variation | 1 | 2017 | 2601 | 0.020 |
Why?
|
Germ-Line Mutation | 1 | 2019 | 1841 | 0.020 |
Why?
|
Aspergillosis | 1 | 2012 | 243 | 0.020 |
Why?
|
Up-Regulation | 1 | 2019 | 4122 | 0.020 |
Why?
|
Diarrhea | 1 | 2017 | 1319 | 0.020 |
Why?
|
Cause of Death | 1 | 2020 | 3725 | 0.020 |
Why?
|
Postmenopause | 1 | 2019 | 2509 | 0.020 |
Why?
|
Intention to Treat Analysis | 1 | 2011 | 422 | 0.020 |
Why?
|
Membrane Transport Proteins | 1 | 2015 | 1035 | 0.020 |
Why?
|
Candidiasis | 1 | 2012 | 363 | 0.020 |
Why?
|
Cell Survival | 1 | 2020 | 5797 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 3804 | 0.020 |
Why?
|
Glucose | 1 | 2001 | 4351 | 0.020 |
Why?
|
Schilling Test | 1 | 1988 | 3 | 0.020 |
Why?
|
Observation | 1 | 2011 | 312 | 0.020 |
Why?
|
Pancreatic Extracts | 1 | 1988 | 6 | 0.020 |
Why?
|
Pancreatin | 1 | 1988 | 9 | 0.020 |
Why?
|
Headache | 1 | 2017 | 1249 | 0.020 |
Why?
|
Epithelial Cells | 1 | 2021 | 3663 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2018 | 6498 | 0.020 |
Why?
|
Viral Load | 1 | 1997 | 3322 | 0.020 |
Why?
|
Glycoproteins | 1 | 2015 | 2208 | 0.020 |
Why?
|
Exocrine Pancreatic Insufficiency | 1 | 1988 | 84 | 0.020 |
Why?
|
Triazoles | 1 | 2012 | 904 | 0.020 |
Why?
|
HIV Core Protein p24 | 2 | 1997 | 245 | 0.020 |
Why?
|
Palliative Care | 1 | 2022 | 3607 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 2015 | 6216 | 0.020 |
Why?
|
Lipase | 1 | 1988 | 324 | 0.020 |
Why?
|
Colonic Neoplasms | 1 | 1998 | 2526 | 0.020 |
Why?
|
Homeodomain Proteins | 1 | 2015 | 2414 | 0.020 |
Why?
|
Liver Diseases | 1 | 2014 | 1302 | 0.020 |
Why?
|
Tumor Suppressor Proteins | 1 | 2015 | 2802 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2017 | 2803 | 0.020 |
Why?
|
Angiography | 1 | 1990 | 1605 | 0.020 |
Why?
|
DNA-Binding Proteins | 1 | 2001 | 9585 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2019 | 9411 | 0.010 |
Why?
|
Structure-Activity Relationship | 1 | 1989 | 3084 | 0.010 |
Why?
|
Protein Binding | 1 | 2015 | 9335 | 0.010 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 1990 | 1131 | 0.010 |
Why?
|
Age Factors | 1 | 2019 | 18416 | 0.010 |
Why?
|
ets-Domain Protein Elk-1 | 1 | 2001 | 39 | 0.010 |
Why?
|
Sequence Tagged Sites | 1 | 2001 | 94 | 0.010 |
Why?
|
Transcription Factors | 1 | 2001 | 12103 | 0.010 |
Why?
|
Hemagglutinins | 1 | 2001 | 113 | 0.010 |
Why?
|
Collagen Type IV | 1 | 2001 | 127 | 0.010 |
Why?
|
Adenocarcinoma | 1 | 1998 | 6315 | 0.010 |
Why?
|
Bacterial Infections | 1 | 1989 | 1403 | 0.010 |
Why?
|
Risk | 1 | 2012 | 9631 | 0.010 |
Why?
|
Child | 2 | 2019 | 79806 | 0.010 |
Why?
|
Cells, Cultured | 2 | 2001 | 18957 | 0.010 |
Why?
|
Rats | 2 | 2001 | 23711 | 0.010 |
Why?
|
Medication Adherence | 1 | 2011 | 2165 | 0.010 |
Why?
|
Parasympathomimetics | 1 | 1998 | 27 | 0.010 |
Why?
|
Bethanechol | 1 | 1998 | 12 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2015 | 15289 | 0.010 |
Why?
|
Patient Care Team | 1 | 2010 | 2511 | 0.010 |
Why?
|
Genes, Dominant | 1 | 2001 | 863 | 0.010 |
Why?
|
Peristalsis | 1 | 1998 | 59 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2017 | 20080 | 0.010 |
Why?
|
Africa, Eastern | 1 | 1998 | 76 | 0.010 |
Why?
|
Muscarinic Agonists | 1 | 1998 | 91 | 0.010 |
Why?
|
Smoking | 1 | 2015 | 9073 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2015 | 22023 | 0.010 |
Why?
|
Isoenzymes | 1 | 2001 | 1690 | 0.010 |
Why?
|
Protein Kinase C | 1 | 2001 | 1199 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2012 | 10344 | 0.010 |
Why?
|
Enzyme Activation | 1 | 2001 | 3602 | 0.010 |
Why?
|
Inflammatory Bowel Diseases | 1 | 1989 | 2421 | 0.010 |
Why?
|
Animals | 3 | 2015 | 167963 | 0.010 |
Why?
|
Head | 1 | 1996 | 922 | 0.010 |
Why?
|
Phosphorylation | 1 | 2001 | 8313 | 0.010 |
Why?
|
Body Height | 1 | 1996 | 1570 | 0.010 |
Why?
|
HIV Infections | 1 | 1996 | 17165 | 0.010 |
Why?
|
Aeromonas | 1 | 1989 | 16 | 0.010 |
Why?
|
Pancrelipase | 1 | 1988 | 7 | 0.010 |
Why?
|
Proto-Oncogene Proteins | 1 | 2001 | 4490 | 0.010 |
Why?
|
Gastric Juice | 1 | 1988 | 59 | 0.010 |
Why?
|
Birth Weight | 1 | 1997 | 2097 | 0.000 |
Why?
|
Pancreatic Function Tests | 1 | 1988 | 69 | 0.000 |
Why?
|
Mice | 1 | 2015 | 81208 | 0.000 |
Why?
|
Trypsin | 1 | 1988 | 496 | 0.000 |
Why?
|
RNA, Messenger | 1 | 2001 | 12766 | 0.000 |
Why?
|
Body Weight | 1 | 1996 | 4611 | 0.000 |
Why?
|
Microspheres | 1 | 1988 | 787 | 0.000 |
Why?
|
Delayed-Action Preparations | 1 | 1988 | 961 | 0.000 |
Why?
|
Child Development | 1 | 1996 | 2285 | 0.000 |
Why?
|
Infant | 2 | 1997 | 36060 | 0.000 |
Why?
|
Saliva | 1 | 1988 | 820 | 0.000 |
Why?
|
Intestine, Small | 1 | 1988 | 1207 | 0.000 |
Why?
|
Cognition | 1 | 1996 | 6957 | 0.000 |
Why?
|
Infant, Newborn | 1 | 1996 | 26181 | 0.000 |
Why?
|
Diagnosis, Differential | 1 | 1989 | 12965 | 0.000 |
Why?
|